De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

Vista Pharmaceuticals Beheer

Beheer criteriumcontroles 2/4

Momenteel beschikken wij niet over voldoende informatie over de CEO.

Belangrijke informatie

Murali Meraga

Algemeen directeur

n/a

Totale compensatie

Percentage CEO-salaris	n/a
Dienstverband CEO	2yrs
Eigendom CEO	11.7%
Management gemiddelde ambtstermijn	2yrs
Gemiddelde ambtstermijn bestuur	4.7yrs

Recente managementupdates

Recent updates

CEO

Murali Meraga

2yrs

Tenure

Mr. Murali Meraga served as Non-Executive Director of Vista Pharmaceuticals Limited from October 2022 until October 14, 2022 and serves as its Managing Director and Executive Director since October 14, 202...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Dhananjaya Alli	Chairman and Whole-Time Director of Science & Technology	29.8yrs	geen gegevens	3.76% ₹ 37.1m
Murali Meraga	MD & Executive Director	2yrs	geen gegevens	11.71% ₹ 115.6m
Pavan Gilaka	Whole-Time Director	2yrs	geen gegevens	10.1% ₹ 99.6m
Suneel Pachipala	Chief Financial Officer	9.5yrs	₹600.00k	geen gegevens
Barkha Jain	Company Secretary & Compliance Officer	less than a year	geen gegevens	geen gegevens

2.0yrs

Gemiddelde duur

Ervaren management: Het managementteam van 524711 wordt beschouwd als ervaren (gemiddelde ambtstermijn 2 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Dhananjaya Alli	Chairman and Whole-Time Director of Science & Technology	29.8yrs	geen gegevens	3.76% ₹ 37.1m
Murali Meraga	MD & Executive Director	2yrs	geen gegevens	11.71% ₹ 115.6m
Pavan Gilaka	Whole-Time Director	2yrs	geen gegevens	10.1% ₹ 99.6m
Stanley Reddy	Non-Executive Director	8.2yrs	geen gegevens	geen gegevens
Mallem Rao	Non Executive Director	15.3yrs	geen gegevens	0.0012% ₹ 11.5k
Divya Chakravarthula	Non-Executive Independent Director	6.7yrs	geen gegevens	geen gegevens
Umesh Banakar	Non-Executive Independent Director	6.7yrs	geen gegevens	geen gegevens
Divakar Yerrabommanahalli	Non Executive Director	5.1yrs	geen gegevens	geen gegevens
Umakanth Katta	Non Executive Director	4.3yrs	geen gegevens	10.28% ₹ 101.5m
Naga Madineni	Independent Director	less than a year	geen gegevens	geen gegevens
Anumala Chandrakumar	Independent Director	less than a year	geen gegevens	geen gegevens
Madhu Anchi	Independent Director	less than a year	geen gegevens	geen gegevens

4.7yrs

Gemiddelde duur

67.5yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van 524711 wordt beschouwd als ervaren (gemiddelde ambtstermijn 4.7 jaar).

Vista Pharmaceuticals Beheer

Beheer criteriumcontroles 2/4

Belangrijke informatie

Recente managementupdates

Vista Pharmaceuticals Limited, Annual General Meeting, Sep 30, 2024

Vista Pharmaceuticals Limited, Annual General Meeting, Sep 30, 2023

Vista Pharmaceuticals Limited Announces the Resignation of Mr. Nishant Talreja from the Post of Company Secretary, Compliance Officer and Key Managerial Personnel

Less than half of directors are independent

Less than half of directors are independent

Vista Pharmaceuticals Limited Announces Executive Changes

Recent updates

First quarter 2025 earnings released: ₹0.15 loss per share (vs ₹0.23 loss in 1Q 2024)

Vista Pharmaceuticals Limited, Annual General Meeting, Sep 30, 2024

Vista Pharmaceuticals Limited to Report Q1, 2025 Results on Aug 13, 2024

New major risk - Financial position

Vista Pharmaceuticals Limited to Report Q4, 2024 Results on May 28, 2024

New major risk - Market cap size

Vista Pharmaceuticals Limited to Report Q3, 2024 Results on Feb 10, 2024

Vista Pharmaceuticals Limited announced that it expects to receive INR 0.533334 million in funding

New major risk - Shareholder dilution

Vista Pharmaceuticals Limited, Annual General Meeting, Sep 30, 2023

Vista Pharmaceuticals Limited to Report Q1, 2024 Results on Aug 12, 2023

Vista Pharmaceuticals Limited Announces the Resignation of Mr. Nishant Talreja from the Post of Company Secretary, Compliance Officer and Key Managerial Personnel

Vista Pharmaceuticals Limited to Report Q4, 2023 Results on May 30, 2023

Vista Pharmaceuticals Limited to Report Q3, 2023 Results on Feb 13, 2023

Investor sentiment improved over the past week

Less than half of directors are independent

Less than half of directors are independent

Vista Pharmaceuticals Limited Announces Executive Changes

Vista Pharmaceuticals Limited Approves Resignation of Narendra Gilaka as Independent Director of the Company

Vista Pharmaceuticals Limited Approves Resignation of Narendra Gilaka as Director

Vista Pharmaceuticals Limited, Annual General Meeting, Sep 29, 2022

Vista Pharmaceuticals Limited to Report Q1, 2023 Results on Aug 13, 2022

Vista Pharmaceuticals Limited Announces Resignation of Akash Bhagadia as Company Secretary and Compliance Officer

Less than half of directors are independent

Third quarter 2022 earnings: Revenues in line with analyst expectations

Vista Pharmaceuticals Limited to Report Q3, 2022 Results on Feb 14, 2022

Full year 2021 earnings released: ₹0.63 loss per share (vs ₹1.21 loss in FY 2020)

Third quarter 2021 earnings released: ₹0.13 loss per share (vs ₹0.07 loss in 3Q 2020)

Vista Pharmaceuticals Limited to Report Q3, 2021 Results on Feb 14, 2021

Vista Pharmaceuticals Limited, Annual General Meeting, Dec 29, 2020

New 90-day high: ₹11.40

New 90-day low: ₹8.30

First quarter earnings released

New 90-day low - ₹8.57

Vista Pharmaceuticals Limited to Report Q1, 2021 Results on Sep 14, 2020

New 90-day low - ₹8.90

Vista Pharmaceuticals Limited to Report Q4, 2020 Results on Jun 30, 2020

CEO

Tenure

Leiderschapsteam

Gemiddelde duur

Bestuursleden

Gemiddelde duur

Gemiddelde leeftijd